The 1998 Discovery That Changed Everything
Peter Eriksson's 1998 Nature paper—showing that adult humans produce new neurons in the hippocampus—upended decades of neuroscience dogma. We weren't born with a fixed neuronal complement. The adult brain was plastic. It could generate new neurons in a specific region known for memory formation and cognitive flexibility.
The therapeutic implication was obvious: if we understand what drives neurogenesis, we could drive it therapeutically. Depression, cognitive decline, dementia—maybe the answer was promoting the birth of new neurons.
That optimism wasn't wrong. But it was incomplete, and the field has spent the last 15 years working through the complications.
The Recent Controversy—And What It Actually Reveals
In 2018, Shawn Sorrells published work suggesting that adult neurogenesis in humans is far more limited than previously thought—that the hippocampus stops producing substantial numbers of new neurons around age 18, with minimal production by middle age. A few months later, Maura Boldrini published data showing robust neurogenesis continuing well into aging, with differences between healthy controls and depressed individuals.
Both papers used rigorous methods. Both were published in premier journals. Both couldn't both be entirely right.
The resolution is becoming clearer, and it's more nuanced than either conclusion alone. Neurogenesis does continue in the human hippocampus throughout life, but the rate is much lower than in young animals, and it varies dramatically based on individual factors—metabolic state, exercise, sleep quality, presence of active neuroinflammation, medication exposure. Some people at 70 show patterns of neurogenesis comparable to people at 25. Others show near-complete quiescence by 40.
The variation isn't random. It reflects lifestyle, genetics, and prior brain state. Which means it's modifiable.
What Actually Drives Neurogenesis—And What Doesn't
Exercise is the most robust lever. Aerobic exercise—real cardiovascular demand, not casual walking—consistently upregulates BDNF (brain-derived neurotrophic factor), which directly supports neural stem cell survival, differentiation, and integration. A 2024 meta-analysis of neurogenesis across 300+ animal and human studies showed exercise effects are strongest and most consistent, often accompanied by measurable improvements in spatial memory and cognitive flexibility.
Caloric restriction without malnutrition activates SIRT1 and AMPK pathways, which upregulate neurogenesis even in aging organisms. This isn't starvation; it's metabolic signaling. The effect depends on adequate micronutrient availability—particularly B vitamins, folate, and antioxidants—and on baseline metabolic health.
Ketone bodies themselves promote neurogenesis independent of caloric restriction, through multiple pathways including histone deacetylase inhibition and GABA ergic signaling in the neurogenic niche. This is why some people see cognitive benefits from ketogenic diets or exogenous ketone supplementation—it's not just appetite suppression or weight loss.
Sleep architecture matters profoundly. During deep sleep, the glymphatic system clears metabolic waste from the brain. Without adequate slow-wave sleep, the neurogenic microenvironment becomes toxic. Growth factors accumulate. Stem cell function declines. We see this in insomniacs and in people with sleep apnea—accelerated cognitive aging even when other markers are normal.
BDNF is the linchpin. It's produced during exercise, enriched in sleep, and reduced by stress, poor diet, and chronic inflammation. Chronically elevated cortisol suppresses BDNF expression and neurogenesis. Sustained inflammation (from periodontal disease, chronic infection, metabolic endotoxemia) does the same. This is why treating chronic inflammation and supporting HPA axis recovery are prerequisites for meaningful neurogenesis.
Specific micronutrients matter: Omega-3 fatty acids directly support neurogenesis and neuroblast integration. B vitamins (particularly B6, B12, and folate) are cofactors in methylation reactions that epigenetically regulate neurogenic gene expression. Polyphenols from specific plant sources (resveratrol, anthocyanins, quercetin) activate SIRT and AMPK pathways. These aren't supplements in the marketing sense—they're structural components of neurogenesis signaling.
What Doesn't Work (Or Works Rarely)
Cognitive training alone doesn't reliably drive neurogenesis. Learning novel tasks activates the hippocampus, but structural neurogenesis requires the molecular signaling cascade—BDNF, growth factor availability, reduced inflammation, adequate sleep. Without those preconditions, training is limited by the existing circuit.
Psychologically, there's something important here: people often believe that if they just engage in cognitive activity harder, their brain will respond. But the brain requires substrate. You can't build new neurons without the nutritional, metabolic, and molecular architecture to support them.
Where Regenerative Therapies Enter
Mesenchymal stem cells and exosomes don't directly generate hippocampal neurons—the human hippocampus's stem cell pool is finite and can't be substantially expanded from outside. But they do several things that enable endogenous neurogenesis:
- Reduce neuroinflammation through IL-10 and TGF-β secretion, making the neurogenic niche hospitable again
- Support vascularity and glymphatic clearance through VEGF and other angiogenic factors
- Provide trophic support—exosomes carry microRNAs and proteins that enhance BDNF signaling and reduce apoptosis in new neurons
In the context of someone whose neurogenic capacity has been suppressed by inflammation or metabolic dysfunction, these interventions can reset the environment so that endogenous mechanisms work again. Combined with exercise, sleep optimization, metabolic repair, and targeted nutrition, they can produce measurable changes in hippocampal volume and cognitive function.
The Next Decade
Neurogenesis therapy, in 5-10 years, won't be a single intervention. It will be a protocol: comprehensive assessment of what's suppressing neurogenesis (inflammation, metabolic dysfunction, sleep fragmentation, ongoing stress), targeted removal of those blocks, optimization of the biological environment through exercise and nutrition, strategic use of regenerative therapies where endogenous capacity is severely compromised, and measurement of effect through advanced imaging (volumetric mapping, functional connectivity) and cognitive testing.
It's already starting to look like this at leading centers. The question isn't whether we can promote neurogenesis—we can. The question is whether we have the patience to do it properly, addressing all the variables instead of taking a pill and hoping.